While AML-related TP53 mutations differ in VAF, mutational site, and functional impact, most of these mutations are missense mutations in cancer-associated TP53 hotspots (e.g., codons 245, 248, and 273) [34], which are represented by our Kasumi-1 (R248Q) and MV4-11 (R248W) cell lines. This evidence concerns the gene TP53 and cancer.